Alzheimer's disease biomarkers: their value in diagnosis and clinical trials.
Biomarkers of Alzheimer's disease may be useful, not only for early diagnosis of the disease, but also for monitoring the progress of drug trials. A number of plasma and cerebrospinal fluid markers are reportedly altered in Alzheimer's disease. So far, no single biomarker can be used to diagnose Alzheimer's disease definitively. Nevertheless, it may eventually be possible to use several markers in combination to obtain sufficient diagnostic accuracy. However, for this to be the case, new specific biomarkers may need to be identified.
Small
David H
DH
Laboratory of Molecular Neurobiology, Department of Pathology, University of Melbourne, Victoria 3010, Australia. davidhs@unimelb.edu.au
D000544:Alzheimer Disease / Q000175:diagnosis* / Q000188:drug therapy; D015415:Biomarkers / Q000032:analysis* / Q000097:blood / Q000134:cerebrospinal fluid; D002986:Clinical Trials as Topic; D006801:Humans; D016896:Treatment Outcome
D015415:Biomarkers